Objective: Respiratory diseases present a challenge for the healthcare system due to their prevalence and clinical impact. The aim of this study was to explore the current situation of hospital pharmacy in the field of respiratory diseases., Method: Observational, cross-sectional study, with a national scope, divided into 2 parts. In an initial phase, the activity and level of pharmaceutical care in respiratory diseases was evaluated through an online questionnaire using REDCap. The survey was addressed to department chiefs and consisted of 17 items, divided into 2 modules: general data and general activity. The second phase was open to hospital pharmacists, with the aim of exploring their opinion on care, training, and improvement needs. The number of items in this phase was 19, divided into 5 modules: general data, pharmaceutical care, competencies, training, and degree of satisfaction., Results: In the first phase, 23 hospitals were included. Most of them (n=20) had a pharmacist in charge of respiratory diseases. However, a large proportion of them dedicated less than 40% of their working day to this activity. The pharmacist's activity occurred at the level of external patients (n=21), hospitalised patients (n=16), and secondarily in management (n=8). Integration is greater in pathologies such as asthma, IPF, pulmonary hypertension, and bronchiectasis. Participation in committees was present in 15 hospitals, with variability in pathologies and degree of involvement. In the second phase, 164 pharmacists participated, who considered pharmaceutical care in cystic fibrosis, asthma, and lung transplant as a priority. 51% considered integration to be adequate and 91% considered it necessary to implement prioritisation criteria. Professional competencies ranged from 6.5 to 6.9 out of 10 points. Only 45% of participants had received specific training in the last 4 years, indicating greater priority for asthma, pulmonary hypertension, and IPF., Conclusions: Most centers have pharmacists specialised in respiratory diseases. However, there is room for improvement in terms of subspecialisation, participation in multidisciplinary committees, implementation of prioritisation criteria, diversification in pathologies treated, as well as greater specific training in this area., Competing Interests: Declaration of competing interest None declared. The authors declare the following collaborations that could be perceived as potentially influencing the results and/or discussion reported in this article: Marta Calvin has received fees in the last 3 years for papers sponsored by AstraZeneca, GlaxoSmithKline, Boehringer Ingelheim, and CSL Behring. Astrid Crespo-Lessmann has received fees in the last 3 years for sponsored presentations from AstraZeneca, GlaxoSmithKline, Sanofi, Orion Pharma, Gebro, Novartis, MSD, and Boehringer Ingelheim; travel and conference attendance fees from GlaxoSmithKline, Chiesi, Novartis; and consultancy fees from GlaxoSmithKline, Sanofi, and AstraZeneca. Jorge Del Estal has received fees in the last 3 years for sponsored lectures from AstraZeneca; travel and conference attendance fees from GlaxoSmithKline; and consultancy fees from AstraZeneca. Daniel Echeverría-Esnal has received fees in the last 3 years for papers sponsored by MSD, Shionogi, and Pfizer; and travel and conference attendance fees from MSD and Pfizer. Sara Garcia Gil has received fees in the last 3 years for presentations sponsored by AstraZeneca and GlaxoSmithKline; travel and conference attendance fees from GlaxoSmithKline; and consultancy fees from GlaxoSmithKline. Noé Garin has received fees in the last 3 years for sponsored presentations from GlaxoSmithKline, Sanofi, and AstraZeneca; and travel and conference attendance fees from PharmaMar and Pfizer. Sonia Jornet has received fees in the last 3 years for sponsored presentations from AstraZeneca, GlaxoSmithKline, and Sanofi; travel and conference attendance fees from Janssen Cilag, AstraZeneca, Sanofi, Gilead, and Pfizer; and consultancy fees from AstraZeneca and GlaxoSmithKline. Hilario Martinez has participated in projects in the last 3 years with grants from Sanofi and AstraZeneca. José Javier Martínez has received fees in the last 3 years for sponsored lectures from AstraZeneca, Sanofi, and GlaxoSmithKline; and travel and conference fees from Gilead. Borja Zarate-Tamames has received fees in the last 3 years for papers sponsored by GlaxoSmithKline; and travel and conference fees from Boehringer Ingelheim and Galapagos Biopharma., (Copyright © 2024 Sociedad Española de Farmacia Hospitalaria (S.E.F.H). Publicado por Elsevier España, S.L.U. All rights reserved.)